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ABSTRACT 
Abetalipoproteinemia is a rare autosomal recessive disease characterized by low lipid levels 
and by the absence of apoB-containing lipoproteins. It is the consequence of microsomal 
triglyceride transfer protein (MTTP) deficiency.      
We report 2 patients with new MTTP mutations. We studied their functional consequences on 
the triglyceride transfer function using duodenal biopsies. We transfected MTTP mutants in 
HepG2 and HeLa cells to investigate their association with protein disulfide isomerase (PDI) 
and their localization at the endoplasmic reticulum. 
These children have a severe abetalipoproteinemia. Both of them had also a mild 
hypogammaglobulinemia. They are compound heterozygotes with c.619G>T and c.1237-
28A>G mutations within MTTP gene. mRNA analysis revealed abnormal splicing with 
deletion of exon 6 and 10, respectively. Deletion of exon 6 (∆6-MTTP) introduced a frame 
shift in the reading frame and a premature stop codon at position 234. Despite ∆6-MTTP and 
∆10-MTTP mutants were not capable of binding PDI, both MTTP mutant proteins normally 
localize at the endoplasmic reticulum. However, these two mutations induce a loss of MTTP 
triglyceride transfer activity.   
These two mutations lead to abnormal truncated MTTP proteins, incapable of binding PDI 
and responsible for the loss of function of MTTP, thereby explaining the severe 
abetalipoproteinemia phenotype of these children. 
 
Keywords: abetalipoproteinemia, MTTP, triglyceride transfer, intestinal HDL, endoplasmic 
reticulum 
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INTRODUCTION 
Abetalipoproteinemia (ABL, OMIM 200100) is a rare autosomal recessive disease 
caused by the deficiency of the microsomal triglyceride transfer protein (MTTP, OMIM 
157147). ABL is characterized by the absence of apolipoprotein B (apoB)-containing 
lipoproteins from plasma. MTTP is a 97 kDa protein, containing 894 amino acids, that forms 
a heterodimer with the 55 kDa protein disulfide isomerase (PDI). MTTP is mainly found in 
the endoplasmic reticulum (ER) of hepatocytes and enterocytes (Wetterau, et al., 1992). 
MTTP is required for the transfer of neutral lipids to nascent apoB-lipoproteins, resulting in 
the secretion of very low-density lipoproteins (VLDL) in the liver or chylomicrons (CM) in 
the intestine. When MTTP is deficient, nascent apoB is degraded by the proteasome (Benoist 
and Grand-Perret, 1997). It differs from familial hypobetalipoproteinemia, displaying 
dysfunctional apoB and leading to the absence of apoB-lipoproteins in the plasma. Familial 
hypobetalipoproteinemia is a co-dominant disorder and even if heterozygotes can be 
asymptomatic, they had low levels of total cholesterol (TC), low density lipoprotein (LDL)-
cholesterol and apoB (OMIM 107730).   
ABL was characterized as the consequence of MTTP absence or dysfunction in 1992 
by Wettereau et al. (Wetterau, et al., 1992). The genetic defects in MTTP gene, located on 
chromosome 4q22-24, were confirmed one year later (Sharp, et al., 1993; Shoulders, et al., 
1993). ABL is a very uncommon disease, which highlights the crucial role of this protein. 
Indeed, the mttp-deficient mice died at embryonic day 10.5 with abnormal neurological 
development (exencephalia) (Raabe, et al., 1998). When a specific inducible intestinal 
deletion of mttp is generated in mice, they presented a phenotype similar to ABL, with 
steatorrhea, growth arrest and decreased cholesterol absorption (Xie, et al., 2006). 
During evolution, MTTP has progressively acquired TG transfer activity in vertebrates 
whereas invertebrate MTTP is known to only transfer phospholipids (Rava and Hussain, 
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2007). Another way to study MTTP functions is to characterize human mutations. This 
approach could help us to determine its active domains that transfer phospholipids, 
cholesterol esters or TG, as well as its binding domains to PDI or to apoB. To our knowledge, 
so far, 40 mutations have been described in 52 patients (Supp. Table S1) (Najah, et al., 2009; 
Zamel, et al., 2008). Here, we report 2 children with a severe form of ABL that are compound 
heterozygotes for MTTP. The new mutations induce deletion of exon 6 and 10 and translation 
of truncated proteins.  
 
Formatted: Font: Italic
Deleted: MTP
Deleted: lementary
Deleted: table 
Deleted: MTP
Page 6 of 78
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
New splicing mutations of MTTP  5 Formatted: Font: Italic
MATERIALS AND METHODS 
Patients: 
We report 2 new cases of ABL, whose diagnosis was performed when AM was a 13 month-
old boy and his sister PM was 6 years-old. They were born from Caucasian non-
consanguineous parents. We received the agreement of both parents for genetic 
investigations. 
Endoscopy and duodenal biopsies: 
Upper gastrointestinal endoscopy was realized under general anesthesia with a Pentax EG-
1870K. Duodenal biopsies were fixed in Bouin for pathology or immediately frozen in liquid 
nitrogen for further investigations (Western blot and MTTP activity assay). For routine 
microscopy, biopsies were embedded in paraformaldehyde and sections were 
hematoxylin/eosin-stained.  
Intestinal MTTP analyses: 
Proteins were extracted from duodenal biopsies to perform a western blot of MTTP. MTTP 
activity was measured by radiolabelled TG transfer from donor to acceptor vesicles as 
previously described (Levy, et al., 2002). 
Plasma sample analyses: 
Blood samples were collected for lipids, lipoproteins, vitamin A and E investigations, and 
ALT. TG and TC were measured by an enzymatic method (Roche). HDL and VLDL-
cholesterol were measured by a dextran/PEG method (Roche). LDL-cholesterol was 
calculated by Friedwald method. ApoA-I and apoB were determined by immuno-turbidimetry 
(Roche). 
Lipid chromatography: 
The FPLC system consisted of a Hitachi L7250 auto-sampler, a L7100 pump system and two 
detectors: L7400 (Hitachi) and UVD170U (Dionex).  20µL of plasma were injected and 
Deleted: ed
Deleted: MTP
Deleted: MTP
Deleted: MTP
Deleted: MTP
Deleted: s
Deleted:  
Page 7 of 78
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
New splicing mutations of MTTP  6 Formatted: Font: Italic
lipoproteins were separated on SuperoseTM6 10/300GL column (GE Healthcare) with 0.15M 
NaCl solution at a flow rate of 0.4mL/min. The column effluent was split equally into two 
lines by a microsplitter 50:50, mixing with cholesterol or triglyceride reagents (Biolabo), thus 
achieving a simultaneous profile from single injection. The two enzymatic reagents were each 
pumped at a rate of 0.2mL/min. Both enzymatic reactions proceeded at 37°C in a Teflon 
reactor coil (15mLx0.4mm id). Proteins were measured directly at 280nm. 
Genomic DNA sequencing of MTTP: 
DNA from patients was extracted from blood samples and then exons and introns of MTTP 
gene (NCBI Reference Sequence: NG_011469.1) were sequenced with Applied ABI Prism. 
mRNA sequencing of MTTP: 
Total RNA was extracted using RNeasy Mini Kit (Qiagen) from either EBV-immortalized B 
lymphocytes for both children or primary lymphocytes for both children and their parents. 
Primary lymphocytes were isolated from blood samples using a ficoll technique. A reverse 
transcription was performed and nested PCR was used to amplify exon 6 and exon 10 with 5’ 
and 3’ flanking regions (see primers in Supp. Table S2). PCR products were separated on 
agarose gel, then extracted with a QIAquick Gel Extraction Kit (Qiagen) and directly inserted 
into pCR2.1 vector (Invitrogen) before sequencing analyses. 
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG 
translation initiation codon in the reference sequence (www.hgvs.org/mutnomen). The 
initiation codon is codon 1. 
Constructs: 
WT-MTTP cDNA was a generous gift of Dr M.Hussain (New-York). We produced by PCR 
WT-MTTP and MTTP mutants with deletions of patients: ∆6-MTTP and ∆10-MTTP. PCR 
fragments (WT-MTTP, ∆6-MTTP and ∆10-MTTP) were digested using BamHI and HindIII 
restriction enzymes, purified with a QIAquick Gel Extraction Kit (Qiagen) and then inserted 
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in pEGFP-N1 or in p2xMyc-N1, generated by replacing the EGFP from pEGFP-N1 with a 
2xMyc epitope. pDsRed2-ER vector (Clontech) was used to encode an ER marker. 
Cell culture and transfection: 
HepG2 (human hepatocellular carcinoma), HeLa (human cervix carcinoma) or Caco-2 
(human epithelial colorectal adenocarcinoma) cells were grown in Dulbecco’s modified 
Eagle’s medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen), 0.1 
mM non essential amino acids (Invitrogen), and 100 µg/ml penicillin/streptomycin 
(Invitrogen) in a humidified atmosphere containing 5% CO2. HepG2 and HeLa cells were 
transfected using GenJuice (Novagen, Merck) or Fugene (Roche) respectively. 
Immunoprecipitation: 
The cells were lysed for 30 min in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% 
Nonidet P-40, 10% glycerol) containing protease and phosphatase inhibitors. Soluble material 
was then incubated overnight at 4°C with 5 µg of monoclonal anti-Myc antibody (clone 
9E10) or polyclonal anti-PDI antibody (DL-11). The antigen-antibody complex was incubated 
with a mix of protein-G and protein-A Sepharose for 1h and then washed in lysis buffer 
containing 0.1% Nonidet P-40. The bound proteins were eluted by boiling the beads in 
Laemmli buffer and analyzed by immunoblotting. 
Immunoblotting: 
The proteins were separated by SDS-polyacrylamide gel electrophoresis under reducing 
conditions, transferred onto nitrocellulose membrane, and analyzed by immunoblotting 
according to standard protocols using indicated antibodies. Anti-MTTP antibody was a 
generous gift of Drs. J. R. Wetterau and H. Jamil. We used a mouse monoclonal antibody 
against Myc (clone 9E10) from BD Biosciences, a rabbit polyclonal antibody against PDI 
(DL-11) from Sigma and a mouse monoclonal antibody against  GFP from Roche. HRP-
labelled secondary antibodies were from Santa-Cruz or Roche Diagnostics. 
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Immunofluorescence experiments: 
HepG2 and HeLa cells were grown on collagen I coated or glass coverslips respectively. Cells 
were fixed in 4% paraformaldehyde, permeabilized with 0.05% saponin, saturated with PBS 
containing 10% fetal bovine serum and incubated with the anti-PDI rabbit polyclonal 
antibody (Sigma) or the anti-Golgin 97 mouse monoclonal antibody (Molecular Probes) and 
then with Cy3-labelled secondary antibody (Jackson Immunoresearch Laboratories). Pictures 
were captured using a Zeiss LSM 510 META confocal microscope equipped with a 63x Plan-
Apochromat objective. 
Immunological investigation: 
Serum immunoglobulin levels were determined by nephelemetry. B lymphocyte phenotype 
and function were analyzed as previously described (Peron, et al., 2008). 
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RESULTS 
Severe form of abetalipoproteinemia: 
When AM was 13-months-old, he presented with a failure to thrive. An intestinal 
malabsorption was suspected on the basis of abdominal distension, abnormal stools (diarrhea 
or constipation) and hydro-aeric levels on abdominal X-ray. An upper gastrointestinal 
endoscopy was performed and revealed a white aspect of duodenal villi characteristic of 
intestinal fat malabsorption and abnormal lipid storage (Figure 1A), as confirmed by 
histology (large fat inclusions located within enterocytes, Figure 1B). Blood analyses revealed 
a severe hypocholesterolemia and hypotriglyceridemia without LDL particles and apoB 
(Table 1). Since parents have normal lipid values as well as apoB and LDL levels, we ruled 
out a hypo-betalipoproteinemia which is a dominant inheritance disease. Thus ABL was 
suspected. They also had an increased level of alanine amino-transferase (ALT) and a 
hyperechogeneic aspect of the liver on ultra-sound scan. Furthermore, both children presented 
a severe vitamin E deficiency secondary to intestinal fat malabsorption. His sister (PM), 6-
years-old at the time of diagnosis, had no rotula reflex (the very early diagnosis of AM 
prevented the development of peripheral neuropathy). However, both of them have no sign of 
retinopathy.  
Abnormal lipoprotein profiles: 
We assessed the blood lipoprotein profiles by FPLC analysis. Both children presented 
a complete absence of LDL and an almost complete absence VLDL in TC and TG moieties 
(Figure 1C and 1D). Although HDL-cholesterol levels are only 20% of control, HDL particles 
remain the only lipid class, with a normal ratio of cholesterol ester to TC (Table 1) reflecting 
a functional lecithin cholesterol acyl-transferase (LCAT) activity. The HDL pattern differs 
between patient and control. Patient had 2 peaks of HDL particles. The early peak is specific 
of the patient while the later one appears at the same time than control, as it is suggested by 
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the concordance of protein chromatogram. HDL particles of the early peak seem to be 
cholesterol-enriched and to have less protein than HDL of the second peak.     
Immunoglobulin synthesis abnormalities: 
Both of these children had also a congenital hypogammaglobulinemia requiring 
regular immunoglobulin substitution. They were diagnosed as immunodeficient on serum 
IgG, IgM and IgA levels that were performed because of a failure to thrive in the first months 
of age (Table 2). There was no protein loosing enteropathy. Mild hypogammaglobulinemia 
was discovered, affecting IgM and IgG in both children. IgA was also slightly decreased in 
the brother AM during the first years of age. AM and PM had normal T and B cell 
populations (data not shown). B cell phenotype was found normal in PM but absence of 
memory switched B cells was observed in the younger brother AM. In contrast, in vitro B cell 
immunoglobulin production was found normal (data not shown).  
MTTP mutations: 
Genomic DNA sequencing of MTTP gene showed 2 different mutations: c.619G>T 
and c.1237-28A>G (Supp. Table S3). The first one c.619G>T was located at the first 
nucleotide of exon 6 and the second one c.1237-28A>G was located within intron 9. In order 
to understand the consequences of such mutations, we extracted mRNA from lymphocytes 
and analyzed MTTP transcripts. MTTP is mainly expressed in the liver and in the intestine, 
but can also be detected from EBV-immortalized B lymphocytes. After reverse transcription 
and PCR amplification, products were analyzed by gel migration, thereby revealing a 
decrease in size for both mutations in patient compared to the control (Figure 2A and 2C). As 
expected, we obtained in control a band at 228 pb and 888 pb for exons 6 and 10 respectively, 
whereas lower fragments were revealed in patient. Those fragments were detected at the size 
of ∼90pb and ∼780pb, suggesting the loss of exons 6 and 10 respectively. Sequencing 
confirmed that these two mutations are responsible for abnormal splicing of exons 6 and 10 
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respectively (Figure 2B and 2D). The first genomic DNA mutation c.619G>T induces a frank 
deletion of exon 6 and a shift in the open reading frame leading to a premature stop codon at 
position 234 and resulting in an abnormal truncated protein consisting of 233 amino acids 
(∼25kDa). The second DNA mutation c.1237-28A>G induces a frank deletion of exon 10 (36 
amino acids), with no shift in the reading frame, leading to a protein of 858 amino acids 
(∼94kDa) (Figure 2E).  
These mutations were also confirmed with sequencing analyses from primary 
lymphocytes from parents and children, meaning that abnormal splicing of MTTP was a 
consequence of genomic mutations and not of EBV immortalization. 
As children are compound heterozygotes, these results confirm the genetic diagnosis 
of ABL. 
Loss of function of MTTP protein: 
Duodenal biopsies were performed and samples were analyzed for MTTP expression 
and activity. In patient, we detected a band with a slight decrease of the apparent MTTP size 
compared to control or Caco-2 cells (Figure 3A), which probably corresponds to ∆10-MTTP 
with the loss of 36 amino acids (3kDa) due to exon 10 deletion. We observed no band at a 
size of 25kDa, corresponding to the expected size of ∆6-MTTP (data not shown), suggesting 
that ∆6-MTTP might be degraded by the proteasome. MTTP activity was also measured on 
these samples and showed a complete loss of TG transfer activity (5-8%/mg protein in control 
versus 0.08-0.8%/mg protein in AM, Figure 3B).  
We further investigated the ability of both ∆6-MTTP and ∆10-MTTP mutants to 
interact with PDI and their subcellular localization by first generating constructs encoding 
GFP- or 2xMyc-tagged WT-MTTP, ∆6-MTTP or ∆10-MTTP. Tagged MTTP mutants as well 
as WT-MTTP were expressed in HeLa cells and analyzed by immunoblotting. We observed 
that ∆6-MTTP and ∆10-MTTP were detected, as well as WT form (Figure 4A and 4B). This 
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is in contrast to the mutant MTTP analysis in duodenal biopsy since ∆6-MTTP could not be 
detected. The overexpression level of tagged proteins might overcome the degradation 
machinery, thereby allowing the detection of a part of ∆6-MTTP and ∆10-MTTP. However, 
∆10-MTTP seemed to be lower expressed compared to WT-MTTP, either expressed as GFP- 
or 2xMyc-∆10-MTTP (quantification in Figure 4C), probably because a part of abnormal 
proteins was degraded by proteasome.  
Since MTTP is localized in the ER through its binding with PDI, we tested the 
association of MTTP mutants with PDI. 2xMyc-tagged MTTP mutant and WT proteins were 
expressed in both HeLa and HepG2 cells and immunoprecipitation was performed using anti-
myc antibody (Figure 4D) or anti-PDI antibody (Figure 4E). As expected, we found that WT-
MTTP interacted with PDI (Figure 4D and 4E, upper panel). By contrast, neither ∆6-MTTP 
nor ∆10-MTTP was able to associate with PDI (Figure 4D and 4E, middle and lower panels).  
We then investigated the cellular localization of WT-MTTP as well as ∆6-MTTP and 
∆10-MTTP. After expression in both HeLa and HepG2 cells, WT-MTTP, ∆6-MTTP and ∆10-
MTTP displayed an identical pattern, showing a reticular localization throughout the cytosol, 
reminiscent of ER staining (Supp. Figure S1). However, in HepG2 cells but not in HeLa cells, 
∆6-MTTP also displays a non specific localization both in the nucleus and throughout the 
cytosol (Supp. Figure S1B, see inset in ∆6-MTTP-GFP), much like GFP alone. This suggests 
that in HepG2 cells, ∆6-MTTP-GFP protein can be degraded, as we observed by 
immunoblotting in duodenal biopsies. Surprisingly, WT-MTTP as well as ∆6-MTTP and 
∆10-MTTP co-localized with ER markers such as ER-DsRed, a red marker consisting of a 
fusion of the DsRed and the ER retention sequence, KDEL (Figure 5A) and PDI (Figure 5B). 
By contrast, no co-localization was observed with cis-Golgi marker such as Golgin 97 (Supp. 
Figure S2) or trans-Golgi marker such as TGN46 (data not shown). 
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Altogether, these data showed that MTTP mutants lost TG transfer activity. They are 
still localized in the ER despite their inability to interact with PDI.  
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DISCUSSION 
MTTP is mainly expressed in enterocytes and hepatocytes where it participates in the 
synthesis of chylomicrons and VLDL respectively. These patients presented fat storage in the 
small intestine (Figure 1A and 1B) and in the liver (as suggested by increased ALT levels and 
hyperechogeneic aspect), as a consequence of MTTP dysfunction.  
Lipids are almost exclusively transported in blood into HDL lipoproteins in ABL 
patients (Figures 1C and 1D and Table 1). These particles are mainly synthesized in 
peripheral tissues to ensure the reverse cholesterol transport to the liver. But, HDL are also 
produced at the basolateral membrane of enterocytes, via ATP Binding Cassette-A1 (ABCA1) 
efflux of cholesterol to apoA-I (Levy, et al., 2007). Cholesterol is transported by enterocytes 
in two  different pathways: the ap B-dependent and the apoB-independent pathways resulting 
respectively in the production of CM or HDL lipoproteins (Iqbal, et al., 2003). Some 
differences exist between these two pathways. Cholesterol ester is only secreted within CM 
while free cholesterol is secreted by both pathways. The apoB-dependent pathway is also 
regulated by MTTP and contributes to cholesterol absorption during post-prandial states. 
MTTP is not required for cholesterol secretion by the apoB-independent pathway that may be 
more important during fasting states. In the human epithelial Caco-2 cell line, Liver X 
Receptor/Retinoid X Receptor activation increases ABCA1 gene expression and basolateral 
efflux of cholesterol in intestinal HDL (Murthy, et al., 2002). In ABL patients, neurological 
impairment (ataxia and peripheral neuropathy) and retinopathy are the consequences of 
vitamin E deficiency. Like cholesterol, these two routes also exist for vitamin E absorption by 
enterocytes (Anwar, et al., 2007). In MTTP-deficient enterocytes, the HDL pathway is used to 
deliver vitamin E. Vitamin E secretion within HDL lipoproteins is not increased by MTTP 
inhibition (Anwar, et al., 2007). This pathway is not as important as chylomicron synthesis 
but, in ABL patients, intestinal HDL represent the only route for lipids or vitamin E from 
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intestine to the liver (Anwar, et al., 2007; Anwar, et al., 2006). These ABL patients have a 
specific class of HDL particles that have a lower density and a lower protein content. 
MTTP is also expressed in natural killer T (NKT) cells. Inhibition of MTTP in fetal 
thymocyte organ culture results in a complete loss of NKT cells (Dougan, et al., 2007). In 
these antigen presenting cells, MTTP loads lipids onto nascent CD1d and regulates 
presentation of glycolipid antigens (Dougan, et al., 2005). MTTP deficiency could impair the 
recycling of CD1d from lysosome to the plasma membrane (Sagiv, et al., 2007). Interestingly, 
both patients present with a hypogammaglobulinemia that was mild but however required 
immunoglobulin substitution. We only found an absence of memory switched B cells in one 
patient while both of them had a normal in vitro immunoglobulin production (Table 2). Since 
such an association between mild B lymphocyte immunodeficiency and abetalipoproteinemia 
has not been previously reported in ABL patients, it is unlikely that MTTP defect is directly 
involved in hypogammaglobulinemia. However, this point should be further investigated, 
looking for a subtle defect in immunoglobulin levels in abetalipoproteinemia patients. 
Recently, Zeissig et al. characterized the loss of CD1 function in ABL patients (Zeissig, et al., 
2010). They found a defect of all antigen-presenting CD1 family members in dendritic cells 
from ABL patients. Similarly to apoB, MTTP deficiency in the ER leads to the degradation of 
group 1 CD1 by the proteasome pathway, which altered activation of NKT cells.  
In these new patients with ABL, we characterized mutations of MTTP by analyzing 
genomic DNA and mRNA products. Sequencing revealed abnormal splicing leading to 
deletion of exon 6 or 10, as a result of two genomic mutations, c.619G>T and c.1237-28A>G 
respectively. c.619G>T is not only a missense mutation (207 Val>Phe), but induces as well an 
abnormal splicing (Mitchell, et al., 1986). The deletion of 140 bp of exon 6 causes a shift in 
the reading frame and a truncated protein because of a premature stop codon in position 234. 
Recently, Najah et al. (Najah, et al., 2009) found similar results with c.619-3T>G mutation 
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located in intron 5 of MTTP. We showed that this truncated protein is not detected in 
duodenal biopsies (data not shown), suggesting that ∆6-MTTP is degraded by the proteasome 
pathway (Pan, et al., 2007). c.1237-28A>G located in intron 9 leads to the frank deletion of 
108 bp of exon 10, with no shift in the reading frame, resulting in the loss of 36 amino acids.  
Human MTTP structure contains an N-terminal β-barrel (βN) (residues 22-297), a 
central α-helical domain (α) (residues 298-603), and two C-terminal β-sheets (βC and βA) 
(residues 604-894). βN is conserved in apoB, lipovitellin, and apolipophorin and may be one 
of the two phospholipid binding sites of MTTP. Helices 4-6, βC and βA domains of MTTP are 
conserved in vertebrates, but not in invertebrates, suggesting that they are involved in TG 
transfer activity (Rava and Hussain, 2007). βN mediates the interaction with the N-terminus of 
apoB; the middle α-helical domain mediates the interaction with both PDI (residues 520-598) 
and apoB (residues 517-603); and the C-terminal mediates the lipid-binding and transfer 
catalytic activity of MTTP (Mann, et al., 1999; Read, et al., 2000). Expression of MTTP 
constructs in HepG2 and HeLa cells showed that ∆6-MTTP and ∆10-MTTP proteins are 
located at ER (Figure 5) but are not associated with PDI (Figure 4D and 4E). MTTP mutants 
might be retained in the ER as defective or misfolded proteins and a part might be 
retrotranslocated to the cytosol for proteasomal degradation. The truncated ∆6-MTTP protein 
only conserved one apoB-binding domain. By contrast, ∆10-MTTP protein is characterized 
by the loss of residues 413-448, that are not directly involved in PDI binding but their loss 
could alter the tertiary structure of the protein. Finally, these residues, corresponding to 
helices 7-9 of the central α-helical domain, belong to a critical domain for TG transfer activity 
as described by Rava and Hussain (Rava and Hussain, 2007). 
In conclusion, we report here two new mutations of MTTP, c.619G>T and c.1237-
28A>G, resulting respectively in ∆6-MTTP protein, a truncated protein of 233 amino acids 
and ∆10-MTTP protein, deleted of exon 10. Despite these mutations do not change ER 
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localization of mutant MTTP proteins, they abolish their binding with PDI and totally 
impaired their TG transfer activity. 
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FIGURES LEGENDS 
 
Figure 1. Diagnosis of abetalipoproteinemia 
(A) Upper gastrointestinal endoscopy performed in patient AM revealed a white aspect of 
duodenal villi, characteristic of lipid storage. (B) Biopsy was performed in duodenum and 
processed for hematoxylin/eosin-staining. The arrow points at the presence of lipid droplets 
within the enterocytes. (C and D) Serum from control or patient (AM) was analyzed using 
FPLC system. Lipoproteins were separated and total cholesterol (C) and triglycerides (D) 
were measured. Profiles are shown for control (Ctrl) and patient (AM). Proteins were only 
showed for patient in C. Note the difference of y-axis (lipid content) between control and 
patient. 
 
Figure 2. Sequence analysis of mutant MTTP transcription products  
(A and C) After mRNA extraction and reverse transcription from control and patient (AM) 
EBV-immortalized lymphocytes, PCR was performed to amplify exon 6 (A) and exon 10 (C) 
with 5’ and 3’ flanking regions. PCR products were analyzed by migration on agarose gel. 
Arrowhead points at the lower band found in patient compared to the control. (B and D) 
Upper bands in the control and lower bands in patients were purified and then cloned into 
pCR2.1 vector before sequencing. In (B), electrophoregrams showed the exon 6 and 5’ and 3’ 
flanking regions with exon 5 and 7 in the control. In the patient, the exon 6 is deleted, leading 
to a frameshift and a premature stop codon. In (D), similarly, electrophoregrams showed the 
exon 10 and 5’ and 3’ flanking regions with exon 9 and 11 in the control. In the patient, the 
exon 10 is deleted. (E) The amino acid sequences corresponding to exons 6 and 10 are shown 
underlined and in blue in the normal MTTP sequence. // determined the deletion of exons 6 or 
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10 in each mutant. For ∆6-MTTP, the frame-shift mutation results in an abnormal sequence 
described in red and in italic. 
   
Figure 3. MTTP expression and activity in duodenal biopsy  
(A) Duodenal biopsy from control (Ctrl) or patient (AM) and Caco-2 cell lysate were 
analyzed by SDS gel electrophoresis and western blotting with antibodies against MTTP. (B) 
The triglyceride transfer activity of MTTP was measured on duodenal biopsy from control or 
patient (AM). Values are expressed as the mean of three independent experiments; standard 
errors are indicated. 
 
Figure 4. Interaction of WT and mutant MTTP with PDI 
(A and B) HeLa cells were transfected or not with WT-MTTP, ∆6-MTTP or ∆10-MTTP 
tagged with EGFP (A) or 2xMyc (B). Cell lysates (100 µg) were analyzed by SDS gel 
electrophoresis and western blotting with antibodies against GFP (A), Myc (B) and Rab5 as 
loading control. Arrowheads point at WT-MTTP, ∆6-MTTP or ∆10-MTTP and arrows point 
at non specific band (ns). Blots in (B) were scanned and the quantification is shown in (C). 
Each experiment was repeated at least 3 times, and (C) shows a representative example. (D 
and E) HeLa cells were transfected with 2xMyc-tagged WT-MTTP, ∆6-MTTP or ∆10-MTTP. 
Cell lysates (Lys) were subjected to immunoprecipitation with (+) or without (-) the anti-myc 
antibody (D) or the anti-PDI antibody (E). Analysis was performed by SDS gel 
electrophoresis and western blotting with antibodies against Myc or PDI. Arrowheads point at 
immunoprecipitated WT-MTTP, ∆6-MTTP or ∆10-MTTP (D) or PDI (E) and arrows point at 
non specific band (ns). IgG HC represents heavy chain of anti-PDI antibody used for 
immunoprecipitation. 
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Figure 5. Localization of WT and mutant MTTP and ER marker 
(A) HeLa cells were co-transfected with GFP-tagged WT-MTTP, ∆6-MTTP or ∆10-MTTP 
and a vector encoding DsRed-ER marker. Cells were then processed for fluorescence 
analysis. (B) HeLa cells were transfected with GFP-tagged WT-MTTP, ∆6-MTTP or ∆10-
MTTP and were then processed for immunofluorescence using anti-PDI antibody. Bar: 10µm. 
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MTTP transcription is controlled by hepatocyte nuclear factor-4α (HNF-4α) 
(Sheena, et al., 2005). Hepatocyte nuclear factor binding element (HNF1A) within the  
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MTTP mRNA when mice are fed with high-cholesterol and high-fat diets (Iqbal, 
et al., 2008). The  
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MTTP promoter variant -579T/T is associated with peripheral arterial disease 
(Schgoer, et al., 2008). The -579G/T polymorphism contributes to fat liver accumulation 
in 3 infected patients with HCV genotype (Zampino, et al., 2008), but could also have a 
role in the steatosis of these children.[A1] 
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MTTP promoter serves as a novel negative insulin-responsive element (Au, et al., 
2008). Forkhead box O1 (FoxO1) mediates insulin-regulated  
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MTTP production, that may be a causative factor for VLDL overproduction and 
hypertriglyceridemia in diabetes (Kamagate, et al., 2008). Regulation of  
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MTTP expression and CM production is controlled by inositol-requiring enzyme 
1beta (IRE1beta), which degrades  
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id 
 
Page 18: [36] Deleted Administrateur 2/7/2011 10:18:00 AM 
 
 AM PM 
Children 
Normal 
Range Father Mother 
Adults 
Normal Range 
Triglycerides 6 1 < 75 mg/dL 77 87 50-150 mg/dL 
Total cholesterol 30 30 < 170 mg/dL 166 235 105-240 mg/dL 
HDL-cholesterol 29 30 > 40 mg/dL 46 69 40-80 mg/dL 
VLDL-cholesterol 10 0 ND 16 17 10-30 mg/dL 
LDL-cholesterol 0 0 < 110 mg/dL 105 148 108-162 mg/dL 
ApoA-I 0.43 0.48 NA 1.25 1.71 1.1-2.1 g/L 
Apo-B 0.02 0.01 < 90 mg/dL 0.68 0.92 0.5-1.35 g/L 
Retinol/RBP 0.68 1.06 0.95-1.06 ND ND  
Tocopherol 0.41 0.16 6-15 mg/L ND ND  
 
NA: no available; ND: not done. 
 
Page 18: [37] Deleted Administrateur 2/7/2011 10:18:00 AM 
 AM, born the 21/01/2004 PM, born the 25/07/1999  
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 29/04/2004 11/10/2005 27/07/2010 30/09/1999 29/11/2005 27/07/2010 
Normal 
range 
IgG 0.95 7.86 6.48 0.33 8.63 5.47 5.6 - 10.4 g/L 
IgA 0.04 0.11 1.11 0.02 1.73 1.67 0.4 - 1.4 g/L 
IgM 0.11 0.67 0.73 0.04 0.44 0.36 0.6 - 1.6 g/L 
 
 
Page 18: [38] Deleted PONS 1/31/2011 5:29:00 PM 
 
 
 exon 6 deletion exon 10 deletion 
AM c.619G>T c.1237-28A>G 
PM c.619G>T c.1237-28A>G 
Father c.619G>T normal 
Mother normal c.1237-28A>G 
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New splicing mutations of MTTP  2 
ABSTRACT 
Abetalipoproteinemia is a rare autosomal recessive disease characterized by low lipid levels 
and by the absence of apoB-containing lipoproteins. It is the consequence of microsomal 
triglyceride transfer protein (MTTP) deficiency.      
We report 2 patients with new MTTP mutations. We studied their functional consequences on 
the triglyceride transfer function using duodenal biopsies. We transfected MTTP mutants in 
HepG2 and HeLa cells to investigate their association with protein disulfide isomerase (PDI) 
and their localization at the endoplasmic reticulum. 
These children have a severe abetalipoproteinemia. Both of them had also a mild 
hypogammaglobulinemia. They are compound heterozygotes with c.619G>T and c.1237-
28A>G mutations within MTTP gene. mRNA analysis revealed abnormal splicing with 
deletion of exon 6 and 10, respectively. Deletion of exon 6 (∆6-MTTP) introduced a frame 
shift in the reading frame and a premature stop codon at position 234. Despite ∆6-MTTP and 
∆10-MTTP mutants were not capable of binding PDI, both MTTP mutant proteins normally 
localize at the endoplasmic reticulum. However, these two mutations induce a loss of MTTP 
triglyceride transfer activity.   
These two mutations lead to abnormal truncated MTTP proteins, incapable of binding PDI 
and responsible for the loss of function of MTTP, thereby explaining the severe 
abetalipoproteinemia phenotype of these children. 
 
Keywords: abetalipoproteinemia, MTTP, triglyceride transfer, intestinal HDL, endoplasmic 
reticulum 
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INTRODUCTION 
Abetalipoproteinemia (ABL, OMIM 200100) is a rare autosomal recessive disease 
caused by the deficiency of the microsomal triglyceride transfer protein (MTTP, OMIM 
157147). ABL is characterized by the absence of apolipoprotein B (apoB)-containing 
lipoproteins from plasma. MTTP is a 97 kDa protein, containing 894 amino acids, that forms 
a heterodimer with the 55 kDa protein disulfide isomerase (PDI). MTTP is mainly found in 
the endoplasmic reticulum (ER) of hepatocytes and enterocytes (Wetterau, et al., 1992). 
MTTP is required for the transfer of neutral lipids to nascent apoB-lipoproteins, resulting in 
the secretion of very low-density lipoproteins (VLDL) in the liver or chylomicrons (CM) in 
the intestine. When MTTP is deficient, nascent apoB is degraded by the proteasome (Benoist 
and Grand-Perret, 1997). It differs from familial hypobetalipoproteinemia, displaying 
dysfunctional apoB and leading to the absence of apoB-lipoproteins in the plasma. Familial 
hypobetalipoproteinemia is a co-dominant disorder and even if heterozygotes can be 
asymptomatic, they had low levels of total cholesterol (TC), low density lipoprotein (LDL)-
cholesterol and apoB (OMIM 107730).   
ABL was characterized as the consequence of MTTP absence or dysfunction in 1992 
by Wettereau et al. (Wetterau, et al., 1992). The genetic defects in MTTP gene, located on 
chromosome 4q22-24, were confirmed one year later (Sharp, et al., 1993; Shoulders, et al., 
1993). ABL is a very uncommon disease, which highlights the crucial role of this protein. 
Indeed, the mttp-deficient mice died at embryonic day 10.5 with abnormal neurological 
development (exencephalia) (Raabe, et al., 1998). When a specific inducible intestinal 
deletion of mttp is generated in mice, they presented a phenotype similar to ABL, with 
steatorrhea, growth arrest and decreased cholesterol absorption (Xie, et al., 2006). 
During evolution, MTTP has progressively acquired TG transfer activity in vertebrates 
whereas invertebrate MTTP is known to only transfer phospholipids (Rava and Hussain, 
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2007). Another way to study MTTP functions is to characterize human mutations. This 
approach could help us to determine its active domains that transfer phospholipids, 
cholesterol esters or TG, as well as its binding domains to PDI or to apoB. To our knowledge, 
so far, 40 mutations have been described in 52 patients (Supp. Table S1) (Najah, et al., 2009; 
Zamel, et al., 2008). Here, we report 2 children with a severe form of ABL that are compound 
heterozygotes for MTTP. The new mutations induce deletion of exon 6 and 10 and translation 
of truncated proteins.  
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MATERIALS AND METHODS 
Patients: 
We report 2 new cases of ABL, whose diagnosis was performed when AM was a 13 month-
old boy and his sister PM was 6 years-old. They were born from Caucasian non-
consanguineous parents. We received the agreement of both parents for genetic 
investigations. 
Endoscopy and duodenal biopsies: 
Upper gastrointestinal endoscopy was realized under general anesthesia with a Pentax EG-
1870K. Duodenal biopsies were fixed in Bouin for pathology or immediately frozen in liquid 
nitrogen for further investigations (Western blot and MTTP activity assay). For routine 
microscopy, biopsies were embedded in paraformaldehyde and sections were 
hematoxylin/eosin-stained.  
Intestinal MTTP analyses: 
Proteins were extracted from duodenal biopsies to perform a western blot of MTTP. MTTP 
activity was measured by radiolabelled TG transfer from donor to acceptor vesicles as 
previously described (Levy, et al., 2002). 
Plasma sample analyses: 
Blood samples were collected for lipids, lipoproteins, vitamin A and E investigations, and 
ALT. TG and TC were measured by an enzymatic method (Roche). HDL and VLDL-
cholesterol were measured by a dextran/PEG method (Roche). LDL-cholesterol was 
calculated by Friedwald method. ApoA-I and apoB were determined by immuno-turbidimetry 
(Roche). 
Lipid chromatography: 
The FPLC system consisted of a Hitachi L7250 auto-sampler, a L7100 pump system and two 
detectors: L7400 (Hitachi) and UVD170U (Dionex). 20µL of plasma were injected and 
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lipoproteins were separated on SuperoseTM6 10/300GL column (GE Healthcare) with 0.15M 
NaCl solution at a flow rate of 0.4mL/min. The column effluent was split equally into two 
lines by a microsplitter 50:50, mixing with cholesterol or triglyceride reagents (Biolabo), thus 
achieving a simultaneous profile from single injection. The two enzymatic reagents were each 
pumped at a rate of 0.2mL/min. Both enzymatic reactions proceeded at 37°C in a Teflon 
reactor coil (15mLx0.4mm id). Proteins were measured directly at 280nm. 
Genomic DNA sequencing of MTTP: 
DNA from patients was extracted from blood samples and then exons and introns of MTTP 
gene (NCBI Reference Sequence: NG_011469.1) were sequenced with Applied ABI Prism. 
mRNA sequencing of MTTP: 
Total RNA was extracted using RNeasy Mini Kit (Qiagen) from either EBV-immortalized B 
lymphocytes for both children or primary lymphocytes for both children and their parents. 
Primary lymphocytes were isolated from blood samples using a ficoll technique. A reverse 
transcription was performed and nested PCR was used to amplify exon 6 and exon 10 with 5’ 
and 3’ flanking regions (see primers in Supp. Table S2). PCR products were separated on 
agarose gel, then extracted with a QIAquick Gel Extraction Kit (Qiagen) and directly inserted 
into pCR2.1 vector (Invitrogen) before sequencing analyses. 
Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG 
translation initiation codon in the reference sequence (www.hgvs.org/mutnomen). The 
initiation codon is codon 1. 
Constructs: 
WT-MTTP cDNA was a generous gift of Dr M.Hussain (New-York). We produced by PCR 
WT-MTTP and MTTP mutants with deletions of patients: ∆6-MTTP and ∆10-MTTP. PCR 
fragments (WT-MTTP, ∆6-MTTP and ∆10-MTTP) were digested using BamHI and HindIII 
restriction enzymes, purified with a QIAquick Gel Extraction Kit (Qiagen) and then inserted 
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in pEGFP-N1 or in p2xMyc-N1, generated by replacing the EGFP from pEGFP-N1 with a 
2xMyc epitope. pDsRed2-ER vector (Clontech) was used to encode an ER marker. 
Cell culture and transfection: 
HepG2 (human hepatocellular carcinoma), HeLa (human cervix carcinoma) or Caco-2 
(human epithelial colorectal adenocarcinoma) cells were grown in Dulbecco’s modified 
Eagle’s medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen), 0.1 
mM non essential amino acids (Invitrogen), and 100 µg/ml penicillin/streptomycin 
(Invitrogen) in a humidified atmosphere containing 5% CO2. HepG2 and HeLa cells were 
transfected using GenJuice (Novagen, Merck) or Fugene (Roche) respectively. 
Immunoprecipitation: 
The cells were lysed for 30 min in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% 
Nonidet P-40, 10% glycerol) containing protease and phosphatase inhibitors. Soluble material 
was then incubated overnight at 4°C with 5 µg of monoclonal anti-Myc antibody (clone 
9E10) or polyclonal anti-PDI antibody (DL-11). The antigen-antibody complex was incubated 
with a mix of protein-G and protein-A Sepharose for 1h and then washed in lysis buffer 
containing 0.1% Nonidet P-40. The bound proteins were eluted by boiling the beads in 
Laemmli buffer and analyzed by immunoblotting. 
Immunoblotting: 
The proteins were separated by SDS-polyacrylamide gel electrophoresis under reducing 
conditions, transferred onto nitrocellulose membrane, and analyzed by immunoblotting 
according to standard protocols using indicated antibodies. Anti-MTTP antibody was a 
generous gift of Drs. J. R. Wetterau and H. Jamil. We used a mouse monoclonal antibody 
against Myc (clone 9E10) from BD Biosciences, a rabbit polyclonal antibody against PDI 
(DL-11) from Sigma and a mouse monoclonal antibody against  GFP from Roche. HRP-
labelled secondary antibodies were from Santa-Cruz or Roche Diagnostics. 
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Immunofluorescence experiments: 
HepG2 and HeLa cells were grown on collagen I coated or glass coverslips respectively. Cells 
were fixed in 4% paraformaldehyde, permeabilized with 0.05% saponin, saturated with PBS 
containing 10% fetal bovine serum and incubated with the anti-PDI rabbit polyclonal 
antibody (Sigma) or the anti-Golgin 97 mouse monoclonal antibody (Molecular Probes) and 
then with Cy3-labelled secondary antibody (Jackson Immunoresearch Laboratories). Pictures 
were captured using a Zeiss LSM 510 META confocal microscope equipped with a 63x Plan-
Apochromat objective. 
Immunological investigation: 
Serum immunoglobulin levels were determined by nephelemetry. B lymphocyte phenotype 
and function were analyzed as previously described (Peron, et al., 2008). 
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RESULTS 
Severe form of abetalipoproteinemia: 
When AM was 13-months-old, he presented with a failure to thrive. An intestinal 
malabsorption was suspected on the basis of abdominal distension, abnormal stools (diarrhea 
or constipation) and hydro-aeric levels on abdominal X-ray. An upper gastrointestinal 
endoscopy was performed and revealed a white aspect of duodenal villi characteristic of 
intestinal fat malabsorption and abnormal lipid storage (Figure 1A), as confirmed by 
histology (large fat inclusions located within enterocytes, Figure 1B). Blood analyses revealed 
a severe hypocholesterolemia and hypotriglyceridemia without LDL particles and apoB 
(Table 1). Since parents have normal lipid values as well as apoB and LDL levels, we ruled 
out a hypo-betalipoproteinemia which is a dominant inheritance disease. Thus ABL was 
suspected. They also had an increased level of alanine amino-transferase (ALT) and a 
hyperechogeneic aspect of the liver on ultra-sound scan. Furthermore, both children presented 
a severe vitamin E deficiency secondary to intestinal fat malabsorption. His sister (PM), 6-
years-old at the time of diagnosis, had no rotula reflex (the very early diagnosis of AM 
prevented the development of peripheral neuropathy). However, both of them have no sign of 
retinopathy.  
Abnormal lipoprotein profiles: 
We assessed the blood lipoprotein profiles by FPLC analysis. Both children presented 
a complete absence of LDL and an almost complete absence VLDL in TC and TG moieties 
(Figure 1C and 1D). Although HDL-cholesterol levels are only 20% of control, HDL particles 
remain the only lipid class, with a normal ratio of cholesterol ester to TC (Table 1) reflecting 
a functional lecithin cholesterol acyl-transferase (LCAT) activity. The HDL pattern differs 
between patient and control. Patient had 2 peaks of HDL particles. The early peak is specific 
of the patient while the later one appears at the same time than control, as it is suggested by 
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the concordance of protein chromatogram. HDL particles of the early peak seem to be 
cholesterol-enriched and to have less protein than HDL of the second peak.     
Immunoglobulin synthesis abnormalities: 
Both of these children had also a congenital hypogammaglobulinemia requiring 
regular immunoglobulin substitution. They were diagnosed as immunodeficient on serum 
IgG, IgM and IgA levels that were performed because of a failure to thrive in the first months 
of age (Table 2). There was no protein loosing enteropathy. Mild hypogammaglobulinemia 
was discovered, affecting IgM and IgG in both children. IgA was also slightly decreased in 
the brother AM during the first years of age. AM and PM had normal T and B cell 
populations (data not shown). B cell phenotype was found normal in PM but absence of 
memory switched B cells was observed in the younger brother AM. In contrast, in vitro B cell 
immunoglobulin production was found normal (data not shown).  
MTTP mutations: 
Genomic DNA sequencing of MTTP gene showed 2 different mutations: c.619G>T 
and c.1237-28A>G (Supp. Table S3). The first one c.619G>T was located at the first 
nucleotide of exon 6 and the second one c.1237-28A>G was located within intron 9. In order 
to understand the consequences of such mutations, we extracted mRNA from lymphocytes 
and analyzed MTTP transcripts. MTTP is mainly expressed in the liver and in the intestine, 
but can also be detected from EBV-immortalized B lymphocytes. After reverse transcription 
and PCR amplification, products were analyzed by gel migration, thereby revealing a 
decrease in size for both mutations in patient compared to the control (Figure 2A and 2C). As 
expected, we obtained in control a band at 228 pb and 888 pb for exons 6 and 10 respectively, 
whereas lower fragments were revealed in patient. Those fragments were detected at the size 
of ∼90pb and ∼780pb, suggesting the loss of exons 6 and 10 respectively. Sequencing 
confirmed that these two mutations are responsible for abnormal splicing of exons 6 and 10 
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respectively (Figure 2B and 2D). The first genomic DNA mutation c.619G>T induces a frank 
deletion of exon 6 and a shift in the open reading frame leading to a premature stop codon at 
position 234 and resulting in an abnormal truncated protein consisting of 233 amino acids 
(∼25kDa). The second DNA mutation c.1237-28A>G induces a frank deletion of exon 10 (36 
amino acids), with no shift in the reading frame, leading to a protein of 858 amino acids 
(∼94kDa) (Figure 2E).  
These mutations were also confirmed with sequencing analyses from primary 
lymphocytes from parents and children, meaning that abnormal splicing of MTTP was a 
consequence of genomic mutations and not of EBV immortalization. 
As children are compound heterozygotes, these results confirm the genetic diagnosis 
of ABL. 
Loss of function of MTTP protein: 
Duodenal biopsies were performed and samples were analyzed for MTTP expression 
and activity. In patient, we detected a band with a slight decrease of the apparent MTTP size 
compared to control or Caco-2 cells (Figure 3A), which probably corresponds to ∆10-MTTP 
with the loss of 36 amino acids (3kDa) due to exon 10 deletion. We observed no band at a 
size of 25kDa, corresponding to the expected size of ∆6-MTTP (data not shown), suggesting 
that ∆6-MTTP might be degraded by the proteasome. MTTP activity was also measured on 
these samples and showed a complete loss of TG transfer activity (5-8%/mg protein in control 
versus 0.08-0.8%/mg protein in AM, Figure 3B).  
We further investigated the ability of both ∆6-MTTP and ∆10-MTTP mutants to 
interact with PDI and their subcellular localization by first generating constructs encoding 
GFP- or 2xMyc-tagged WT-MTTP, ∆6-MTTP or ∆10-MTTP. Tagged MTTP mutants as well 
as WT-MTTP were expressed in HeLa cells and analyzed by immunoblotting. We observed 
that ∆6-MTTP and ∆10-MTTP were detected, as well as WT form (Figure 4A and 4B). This 
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is in contrast to the mutant MTTP analysis in duodenal biopsy since ∆6-MTTP could not be 
detected. The overexpression level of tagged proteins might overcome the degradation 
machinery, thereby allowing the detection of a part of ∆6-MTTP and ∆10-MTTP. However, 
∆10-MTTP seemed to be lower expressed compared to WT-MTTP, either expressed as GFP- 
or 2xMyc-∆10-MTTP (quantification in Figure 4C), probably because a part of abnormal 
proteins was degraded by proteasome.  
Since MTTP is localized in the ER through its binding with PDI, we tested the 
association of MTTP mutants with PDI. 2xMyc-tagged MTTP mutant and WT proteins were 
expressed in both HeLa and HepG2 cells and immunoprecipitation was performed using anti-
myc antibody (Figure 4D) or anti-PDI antibody (Figure 4E). As expected, we found that WT-
MTTP interacted with PDI (Figure 4D and 4E, upper panel). By contrast, neither ∆6-MTTP 
nor ∆10-MTTP was able to associate with PDI (Figure 4D and 4E, middle and lower panels).  
We then investigated the cellular localization of WT-MTTP as well as ∆6-MTTP and 
∆10-MTTP. After expression in both HeLa and HepG2 cells, WT-MTTP, ∆6-MTTP and ∆10-
MTTP displayed an identical pattern, showing a reticular localization throughout the cytosol, 
reminiscent of ER staining (Supp. Figure S1). However, in HepG2 cells but not in HeLa cells, 
∆6-MTTP also displays a non specific localization both in the nucleus and throughout the 
cytosol (Supp. Figure S1B, see inset in ∆6-MTTP-GFP), much like GFP alone. This suggests 
that in HepG2 cells, ∆6-MTTP-GFP protein can be degraded, as we observed by 
immunoblotting in duodenal biopsies. Surprisingly, WT-MTTP as well as ∆6-MTTP and 
∆10-MTTP co-localized with ER markers such as ER-DsRed, a red marker consisting of a 
fusion of the DsRed and the ER retention sequence, KDEL (Figure 5A) and PDI (Figure 5B). 
By contrast, no co-localization was observed with cis-Golgi marker such as Golgin 97 (Supp. 
Figure S2) or trans-Golgi marker such as TGN46 (data not shown). 
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Altogether, these data showed that MTTP mutants lost TG transfer activity. They are 
still localized in the ER despite their inability to interact with PDI.  
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DISCUSSION 
MTTP is mainly expressed in enterocytes and hepatocytes where it participates in the 
synthesis of chylomicrons and VLDL respectively. These patients presented fat storage in the 
small intestine (Figure 1A and 1B) and in the liver (as suggested by increased ALT levels and 
hyperechogeneic aspect), as a consequence of MTTP dysfunction.  
Lipids are almost exclusively transported in blood into HDL lipoproteins in ABL 
patients (Figures 1C and 1D and Table 1). These particles are mainly synthesized in 
peripheral tissues to ensure the reverse cholesterol transport to the liver. But, HDL are also 
produced at the basolateral membrane of enterocytes, via ATP Binding Cassette-A1 (ABCA1) 
efflux of cholesterol to apoA-I (Levy, et al., 2007). Cholesterol is transported by enterocytes 
in two  different pathways: the apoB-dependent and the apoB-independent pathways resulting 
respectively in the production of CM or HDL lipoproteins (Iqbal, et al., 2003). Some 
differences exist between these two pathways. Cholesterol ester is only secreted within CM 
while free cholesterol is secreted by both pathways. The apoB-dependent pathway is also 
regulated by MTTP and contributes to cholesterol absorption during post-prandial states. 
MTTP is not required for cholesterol secretion by the apoB-independent pathway that may be 
more important during fasting states. In the human epithelial Caco-2 cell line, Liver X 
Receptor/Retinoid X Receptor activation increases ABCA1 gene expression and basolateral 
efflux of cholesterol in intestinal HDL (Murthy, et al., 2002). In ABL patients, neurological 
impairment (ataxia and peripheral neuropathy) and retinopathy are the consequences of 
vitamin E deficiency. Like cholesterol, these two routes also exist for vitamin E absorption by 
enterocytes (Anwar, et al., 2007). In MTTP-deficient enterocytes, the HDL pathway is used to 
deliver vitamin E. Vitamin E secretion within HDL lipoproteins is not increased by MTTP 
inhibition (Anwar, et al., 2007). This pathway is not as important as chylomicron synthesis 
but, in ABL patients, intestinal HDL represent the only route for lipids or vitamin E from 
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intestine to the liver (Anwar, et al., 2007; Anwar, et al., 2006). These ABL patients have a 
specific class of HDL particles that have a lower density and a lower protein content. 
MTTP is also expressed in natural killer T (NKT) cells. Inhibition of MTTP in fetal 
thymocyte organ culture results in a complete loss of NKT cells (Dougan, et al., 2007). In 
these antigen presenting cells, MTTP loads lipids onto nascent CD1d and regulates 
presentation of glycolipid antigens (Dougan, et al., 2005). MTTP deficiency could impair the 
recycling of CD1d from lysosome to the plasma membrane (Sagiv, et al., 2007). Interestingly, 
both patients present with a hypogammaglobulinemia that was mild but however required 
immunoglobulin substitution. We only found an absence of memory switched B cells in one 
patient while both of them had a normal in vitro immunoglobulin production (Table 2). Since 
such an association between mild B lymphocyte immunodeficiency and abetalipoproteinemia 
has not been previously reported in ABL patients, it is unlikely that MTTP defect is directly 
involved in hypogammaglobulinemia. However, this point should be further investigated, 
looking for a subtle defect in immunoglobulin levels in abetalipoproteinemia patients. 
Recently, Zeissig et al. characterized the loss of CD1 function in ABL patients (Zeissig, et al., 
2010). They found a defect of all antigen-presenting CD1 family members in dendritic cells 
from ABL patients. Similarly to apoB, MTTP deficiency in the ER leads to the degradation of 
group 1 CD1 by the proteasome pathway, which altered activation of NKT cells.  
In these new patients with ABL, we characterized mutations of MTTP by analyzing 
genomic DNA and mRNA products. Sequencing revealed abnormal splicing leading to 
deletion of exon 6 or 10, as a result of two genomic mutations, c.619G>T and c.1237-28A>G 
respectively. c.619G>T is not only a missense mutation (207 Val>Phe), but induces as well an 
abnormal splicing (Mitchell, et al., 1986). The deletion of 140 bp of exon 6 causes a shift in 
the reading frame and a truncated protein because of a premature stop codon in position 234. 
Recently, Najah et al. (Najah, et al., 2009) found similar results with c.619-3T>G mutation 
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located in intron 5 of MTTP. We showed that this truncated protein is not detected in 
duodenal biopsies (data not shown), suggesting that ∆6-MTTP is degraded by the proteasome 
pathway (Pan, et al., 2007). c.1237-28A>G located in intron 9 leads to the frank deletion of 
108 bp of exon 10, with no shift in the reading frame, resulting in the loss of 36 amino acids.  
Human MTTP structure contains an N-terminal β-barrel (βN) (residues 22-297), a 
central α-helical domain (α) (residues 298-603), and two C-terminal β-sheets (βC and βA) 
(residues 604-894). βN is conserved in apoB, lipovitellin, and apolipophorin and may be one 
of the two phospholipid binding sites of MTTP. Helices 4-6, βC and βA domains of MTTP are 
conserved in vertebrates, but not in invertebrates, suggesting that they are involved in TG 
transfer activity (Rava and Hussain, 2007). βN mediates the interaction with the N-terminus of 
apoB; the middle α-helical domain mediates the interaction with both PDI (residues 520-598) 
and apoB (residues 517-603); and the C-terminal mediates the lipid-binding and transfer 
catalytic activity of MTTP (Mann, et al., 1999; Read, et al., 2000). Expression of MTTP 
constructs in HepG2 and HeLa cells showed that ∆6-MTTP and ∆10-MTTP proteins are 
located at ER (Figure 5) but are not associated with PDI (Figure 4D and 4E). MTTP mutants 
might be retained in the ER as defective or misfolded proteins and a part might be 
retrotranslocated to the cytosol for proteasomal degradation. The truncated ∆6-MTTP protein 
only conserved one apoB-binding domain. By contrast, ∆10-MTTP protein is characterized 
by the loss of residues 413-448, that are not directly involved in PDI binding but their loss 
could alter the tertiary structure of the protein. Finally, these residues, corresponding to 
helices 7-9 of the central α-helical domain, belong to a critical domain for TG transfer activity 
as described by Rava and Hussain (Rava and Hussain, 2007). 
In conclusion, we report here two new mutations of MTTP, c.619G>T and c.1237-
28A>G, resulting respectively in ∆6-MTTP protein, a truncated protein of 233 amino acids 
and ∆10-MTTP protein, deleted of exon 10. Despite these mutations do not change ER 
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localization of mutant MTTP proteins, they abolish their binding with PDI and totally 
impaired their TG transfer activity. 
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FIGURES LEGENDS 
 
Figure 1. Diagnosis of abetalipoproteinemia 
(A) Upper gastrointestinal endoscopy performed in patient AM revealed a white aspect of 
duodenal villi, characteristic of lipid storage. (B) Biopsy was performed in duodenum and 
processed for hematoxylin/eosin-staining. The arrow points at the presence of lipid droplets 
within the enterocytes. (C and D) Serum from control or patient (AM) was analyzed using 
FPLC system. Lipoproteins were separated and total cholesterol (C) and triglycerides (D) 
were measured. Profiles are shown for control (Ctrl) and patient (AM). Proteins were only 
showed for patient in C. Note the difference of y-axis (lipid content) between control and 
patient. 
 
Figure 2. Sequence analysis of mutant MTTP transcription products  
(A and C) After mRNA extraction and reverse transcription from control and patient (AM) 
EBV-immortalized lymphocytes, PCR was performed to amplify exon 6 (A) and exon 10 (C) 
with 5’ and 3’ flanking regions. PCR products were analyzed by migration on agarose gel. 
Arrowhead points at the lower band found in patient compared to the control. (B and D) 
Upper bands in the control and lower bands in patients were purified and then cloned into 
pCR2.1 vector before sequencing. In (B), electrophoregrams showed the exon 6 and 5’ and 3’ 
flanking regions with exon 5 and 7 in the control. In the patient, the exon 6 is deleted, leading 
to a frameshift and a premature stop codon. In (D), similarly, electrophoregrams showed the 
exon 10 and 5’ and 3’ flanking regions with exon 9 and 11 in the control. In the patient, the 
exon 10 is deleted. (E) The amino acid sequences corresponding to exons 6 and 10 are shown 
underlined and in blue in the normal MTTP sequence. // determined the deletion of exons 6 or 
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10 in each mutant. For ∆6-MTTP, the frame-shift mutation results in an abnormal sequence 
described in red and in italic. 
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Figure 3. MTTP expression and activity in duodenal biopsy  
(A) Duodenal biopsy from control (Ctrl) or patient (AM) and Caco-2 cell lysate were 
analyzed by SDS gel electrophoresis and western blotting with antibodies against MTTP. (B) 
The triglyceride transfer activity of MTTP was measured on duodenal biopsy from control or 
patient (AM). Values are expressed as the mean of three independent experiments; standard 
errors are indicated. 
 
Figure 4. Interaction of WT and mutant MTTP with PDI 
(A and B) HeLa cells were transfected or not with WT-MTTP, ∆6-MTTP or ∆10-MTTP 
tagged with EGFP (A) or 2xMyc (B). Cell lysates (100 µg) were analyzed by SDS gel 
electrophoresis and western blotting with antibodies against GFP (A), Myc (B) and Rab5 as 
loading control. Arrowheads point at WT-MTTP, ∆6-MTTP or ∆10-MTTP and arrows point 
at non specific band (ns). Blots in (B) were scanned and the quantification is shown in (C). 
Each experiment was repeated at least 3 times, and (C) shows a representative example. (D 
and E) HeLa cells were transfected with 2xMyc-tagged WT-MTTP, ∆6-MTTP or ∆10-MTTP. 
Cell lysates (Lys) were subjected to immunoprecipitation with (+) or without (-) the anti-myc 
antibody (D) or the anti-PDI antibody (E). Analysis was performed by SDS gel 
electrophoresis and western blotting with antibodies against Myc or PDI. Arrowheads point at 
immunoprecipitated WT-MTTP, ∆6-MTTP or ∆10-MTTP (D) or PDI (E) and arrows point at 
non specific band (ns). IgG HC represents heavy chain of anti-PDI antibody used for 
immunoprecipitation. 
 
Figure 5. Localization of WT and mutant MTTP and ER marker 
(A) HeLa cells were co-transfected with GFP-tagged WT-MTTP, ∆6-MTTP or ∆10-MTTP 
and a vector encoding DsRed-ER marker. Cells were then processed for fluorescence 
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analysis. (B) HeLa cells were transfected with GFP-tagged WT-MTTP, ∆6-MTTP or ∆10-
MTTP and were then processed for immunofluorescence using anti-PDI antibody. Bar: 10µm. 
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TABLES 
 
Table 1. Clinical and biological findings in abetalipoproteinemia patients and their 
parents 
 AM PM 
Children 
Normal 
Range Father Mother 
Adults 
Normal Range 
Age (year) 1.3 5.9  40 37  
Weight (kg) 8.2 19  NA NA  
Height (cm) 75 111  NA NA  
Triglycerides 6 1 < 75 mg/dL 77 87 50-150 mg/dL 
Free cholesterol 7,9 6,6 NA ND ND  
Esterified cholesterol 22,1 23,4 NA ND ND  
Total cholesterol 30 30 < 170 mg/dL 166 235 105-240 mg/dL 
HDL-cholesterol 29 30 > 40 mg/dL 46 69 40-80 mg/dL 
VLDL-cholesterol 10 0 ND 16 17 10-30 mg/dL 
LDL-cholesterol 0 0 < 110 mg/dL 105 148 108-162 mg/dL 
ApoA-I 0.43 0.48 NA 1.25 1.71 1.1-2.1 g/L 
Apo-B 0.02 0.01 < 90 mg/dL 0.68 0.92 0.5-1.35 g/L 
Retinol/RBP 0.68 1.06 0.95-1.06 ND ND  
Tocopherol 0.41 0.16 6-15 mg/L ND ND  
ALT 60 60 < 36 IU/L ND ND  
AST 76 76 < 50 IU/L ND ND  
 
NA: not available; ND: not done. 
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Table 2. Immunoglobulin levels 
 AM, born the 21/01/2004 PM, born the 25/07/1999  
 29/04/2004 11/10/2005 27/07/2010 30/09/1999 29/11/2005 27/07/2010 
Normal 
range 
IgG 0.95 7.86 6.48 0.33 8.63 5.47 5.6 - 10.4 g/L 
IgA 0.04 0.11 1.11 0.02 1.73 1.67 0.4 - 1.4 g/L 
IgM 0.11 0.67 0.73 0.04 0.44 0.36 0.6 - 1.6 g/L 
 
Immunoglobulin levels of both patients were reported at the diagnosis of 
hypogammaglobulinemia, just after the diagnosis of abetalipoproteinemia and at the last 
follow-up. 
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Supplementary Table S1. Description of MTTP mutations reported in the literature 
exon/intron mutations exon/intron mutations consequency 
number  
of 
patients references 
intron 9, c.1237-1G>A, 
maternal unidisomy 
intron 9, c.1237-1G>A, 
maternal unidisomy 
abnormal splicing site, 
exon 10 deletion  1 Yang, et al., 1999 
exon 13, c.1820delG exon 13, c.1820delG abnormal reading frame 1 Wang, et al., 1999 
exon 16, c.2237G>A exon 18, c.2524A>T p.G746E  / p.K842X  1 Wang, et al., 1999 
exon 12, c.1619G>A exon 12, c.1619G>A p.R540H  1 Wang, et al., 1999 
exon 18, c.2593G>T exon 18, c.2593G>T p.G865X  7 
Benayoun, et al., 2007 
Ricci, et al., 1995 
Wang, et al., 1999   
exon 10, c.1342A>T intron 12, 1769+1G>A  
p.K448X / abnormal 
splicing site 1 Wang, et al., 1999 
exon 12, c.1769G>T exon 12, c.1769G>T p.S590I  2 
Al Shali, et al., 2003 
Wang, et al., 1999 
exon 11, c.1389delA exon 11, c.1389delA abnormal reading frame 1 Ohashi, et al., 2000 
exon 4, c.419insA exon 4, c.419insA abnormal reading frame 3 
Al Shali, et al., 2003 
Berthier, et al., 2004 
Narcisi, et al., 1995 
Ohashi, et al., 2000 
exon 13, c.1783C>T intron 15, c.2218-2A>G 
p.R595X, abnormal 
splicing site 1 Ohashi, et al., 2000 
exon 16, c.2338A>T exon 16, c.2338A>T p.D780Y 1 Ohashi, et al., 2000 
exon 9, 
c.1228delCCCinsT 
exon 9, 
c.1228delCCCinsT abnormal reading frame 1 Di Leo, et al., 2005 
intron 9, c.1237-1G>A NA 
abnormal splicing site, 
exon 10 deletion  1 Di Leo, et al., 2005 
exon 9, c.1151 A>C exon14, c.1982 G>C p.D384A / p.G661A 1 Di Leo, et al., 2005 
exon 15, c.2212delT exon 15, c.2212delT abnormal reading frame 3 
Benayoun, et al., 2007 
Narcisi, et al., 1995 
intron 1, c.148-2A>G intron 1, c.148-2A>G abnormal splicing site 2 Benayoun, et al., 2007 
exon 3, c.307A>T exon 3, c.307A>T p.K103X 1 Benayoun, et al., 2007 
large deletion of 481 kb large deletion of 481 kb 
loss of MTP and 8 other 
genes 1 Benayoun, et al., 2007 
exon 15, c.2076-
39_2303+52del319 
exon 15, c.2076-
39_2303+52del319 exon 15 deletion 1 
Vongsuvanh, et 
al., 2007 
exon 2, c.215delC exon 2, c.215delC abnormal reading frame 1 Sharp, et al., 1993 
exon 13, c.1783C>T exon 13, c.1783C>T p.R595X 2 
Chardon, et al., 2009 
Sharp, et al., 1993 
exon 17, 
c.2346insACTG 
exon 17, 
c.2346insACTG abnormal reading frame 1 Heath, et al., 1997 
exon1, c.59del17 exon1, c.59del17 abnormal reading frame 1 Chardon, et al., 2009 
exon 5, c.582C>A exon 5, c.582C>A p.Cys194X 2 Chardon, et al., 2009 
intron 5, c.619-3T>G intron 5, c.619-3T>G 
abnormal splicing site, 
exon 6 deletion  1 Najah, et al., 2009 
exon 8, c.923G>A exon 8, c.923G>A p.W308X 1 Najah, et al., 2009 
exon 10, c.1237-
1344del107 exon 12, c.1619G>A 
exon 10 deletion / 
p.R540H  1 Rehberg JBC 1996 
exon 9, c.1147delA exon 9, c.1147delA abnormal reading frame 1 Narcisi, et al., 1995 
intron 10, c.1344+5del7 intron 10, c.1344+5del7 abnormal splicing site 1 Narcisi, et al., 1995 
exon 4, c.419insA exon 11, 1401insA abnormal reading frame 1 Narcisi, et al., 1995 
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intron 13, c.1867+1G>A intron 14, c.1990-1G>A  
abnormal splicing site / 
abnormal splicing site 1 Narcisi, et al., 1995 
exon 4, c.419insA intron 13, c.1867+5G>A 
abnormal reading frame 
/ abnormal splicing site 1 Narcisi, et al., 1995 
intron 13, c.1867+5G>A intron 13, c.1867+5G>A abnormal splicing site 2 
Narcisi, et al., 1995 
Shoulders, et al.,  1993 
intron 1, 147+2T>C exon 4, c.419insA 
abnormal splicing site / 
abnormal reading frame 1 Dische, et al., 1970 
intron 1, 147+1G>C exon 12, c.1692T>C 
abnormal splicing site / 
p.I564T 1 Sakamoto, et al., 2006 
exon 6, c.619G>T intron 9, c.1237-28A>G 
abnormal splicing site / 
abnormal splicing site 2 this report 
 
 
Supplementary Table S2. PCR primers 
 
 
Supplementary Table S3. Genomic mutations of MTTP  
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Supplementary Figure S1: Localization of WT and mutant MTTP 
HeLa cells (A) or HepG2 cells (B) were transfected with GFP-tagged WT-MTTP, ∆6-MTTP 
or ∆10-MTTP and were then processed for immunofluorescence. Bar: 10µm. 
 
Supplementary Figure S2: Localization of WT and mutant MTTP and Golgi marker 
 
HeLa cells were transfected with GFP-tagged WT-MTTP, ∆6-MTTP or ∆10-MTTP and were 
then processed for immunofluorescence using anti-Golgin 97 antibody. Bar: 10µm  
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